Drugs Targeted Protein Degradation Therapies 
SugarCone Biotech
OCTOBER 6, 2024
It is important to be clear that this is a unique degrader strategy and not at all like ProTAC or ProMAB technologies that targets proteins by binding them to the E3-ligase controlled degradation pathway. That is a complex field that has struggled to bring therapies to approval (see [link] ).
Drug Hunter
MAY 21, 2023
This article highlights six recent articles of interest in the field of targeted protein degradation including but not limited to potentially new ligases, recruiting motifs, and a discussion on the feasibility of CNS-penetrant degraders. ’23: DCAF1, on CNS Degraders, and More appeared first on Drug Hunter.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Hunter
JUNE 25, 2023
This edition includes Maze’s glycogen synthase 1 (GYS1) inhibitors that were recently licensed to Sanofi, allosteric androgen receptor (AR) modulators that may be of interest to targeted protein degradation researchers, and brain-penetrant HER2 and ROCK2 inhibitors.
Zobio
MARCH 8, 2023
In person Molecular glues and targeted protein degraders are changing the landscape of drug discovery. They show great potential for treating diseases such as cancer, infectious, inflammatory, andneurodegenerative diseases, especially for those with “undruggable” pathogenic protein targets.
Zobio
MARCH 8, 2023
In person Molecular glues and targeted protein degraders are changing the landscape of drug discovery. They show great potential for treating diseases such as cancer, infectious, inflammatory, andneurodegenerative diseases, especially for those with “undruggable” pathogenic protein targets.
Covalent Modifiers
FEBRUARY 1, 2024
Therefore, understanding mechanisms by which acquired mutations in BTK confer drug resistance and developing new therapies to overcome resistance are critically important. This effort included evaluation of BTK degradation in patients with CLL treated in a phase 1 clinical trial of NX-2127, a first-in-class BTK degrader (NCT04830137).
Drug Target Review
OCTOBER 4, 2023
Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 1 However, efforts proved less effective than the original drugs, owing mostly to insufficient toxicity against cancer cells.
Expert insights. Personalized for you.
73 
Let's personalize your content